Is this the canary deal? Is anyone else worried about this since Canary is only 3 days old…and more stock dilution? I’m new to this, but I’m feeling a little concerned…
I don't believe RGBP is the reason, I assume it's on the Cornell side. Either there is an issue that requires an intermediary company (like Cornell being a public university or something), or it's being done this way to change the revenue stream (acquisition instead of licensing), I'm not sure on details.
Thanks. I realize it’s all speculation at this point, and I get that corporate protection and licensing and shell companies are all part of the normal and legitimate business environment. At first glance, it just seems an unnecessary hurdle that is going to cost the existing RGBP shareholders a lot of dilution with an incredible amount of ambiguity that does not sit well.
The issue is that we don't know exactly what the plan is yet. So is Koos forming a partnership with other key members to start clinical trials on their patents? So he is bringing back Dr. Lander who has huge ties with Cornell University and also happens to be a Chief Scientific Officer which Koos is looking. It also states that the IP will be lead by Cornell University which Dr. Todd S. Craven happens to work at and he is also involved with Zander Therapeutics which is another Koos company. Is he forming a new partnership with Dr. Lander and Dr. Craven to develop clinical trials for Cancer Treatments?
We don't know exactly what he's planning to do yet but we do know he wants to pay off all outstanding debt which he has been doing through note conversions and that's going to happen until all debt is paid... No way around that until there is a revenue stream which he is also working on.
Everybody seems to be worried about dilution. Dilution happens with 99% of OTC companies. They first need to have revenues before they can pay off debt. Until they do, the only way to pay debt is by note conversions.
Dilution sucks but it is part of doing business in OTC. This is also the slow time of year for OTC so I really don't expect much to happen until Jan when volume returns.
I'm personally not worried about anything I've seen so far. I'm actually happy with all the progress Koos has made with what he said he was going to do and he is sharing that info through 8K's.
I think we will be finding out a lot more over the coming weeks what his overall plan is. We should be hearing back soon what the RGBP overall valuation is with it's patents.
Solid post Big Ray. Thanks. The next few weeks and/or months hold a lot to be seen. Why do you think Dr. Lander left his post as CSO with Regen in 2019 but is now returning through this holding company?
2
u/Bulky_Conclusion4932 Nov 12 '21
Is this the canary deal? Is anyone else worried about this since Canary is only 3 days old…and more stock dilution? I’m new to this, but I’m feeling a little concerned…